Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 119-125

  Nguyen, Carvell T ^a   Fu, Alex Z ^a   Gilligan, Timothy D ^a   Wells, Brian J ^a   Klein, Eric A ^a   Kattan, Michael W ^a   Stephenson, Andrew J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; GERM CELL TUMOR; HEALTH CARE UTILIZATION; HUMAN; LIFE EXPECTANCY; LYMPH NODE DISSECTION; MORBIDITY; ORCHIECTOMY; PATIENT PARTICIPATION; PRIORITY JOURNAL; TESTIS NONSEMINOMA CANCER; THEORETICAL MODEL; TREATMENT OUTCOME; DECISION SUPPORT SYSTEM; LYMPHADENECTOMY; MALE; MORTALITY; NEOPLASM; PATHOLOGY; TESTIS TUMOR;

DECISION SUPPORT TECHNIQUES; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS;

EID: 73949085749     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.0400     Document Type: Article

References (65)

1. Stephenson AJ, Bosl GJ, Motzer RJ, et al: Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: Impact of patient selection factors on outcome. J Clin Oncol 23:2781-2788, 2005
2. Stephenson AJ, Bosl GJ, Bajorin DF, et al: Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 174:557-560, 2005
3. Donohue JP, Thornhill JA, Foster RS, et al: Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): Modifications of technique and impact on ejaculation. J Urol 149:237-243, 1993
4. Hermans BP, Sweeney CJ, Foster RS, et al: Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 163: 1721-1724, 2000
5. Nicolai N, Miceli R, Artusi R, et al: A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol 171:172-176, 2004
6. Albers P, Siener R, Krege S, et al: Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26:2966-2972, 2008
7. Bohlen D, Borner M, Sonntag RW, et al: Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161:1148-1152, 1999
8. Cullen MH, Stenning SP, Parkinson MC, et al: Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A Medical Research Council report. J Clin Oncol 14:1106-1113, 1996
9. Oliver RT, Ong J, Shamash J, et al: Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 63: 556-561, 2004
10. Amato RJ, Ro JY, Ayala AG, et al: Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 63:144-148, 2004; discussion 148-9, 2004
11. Dearnaley DP, Fossa SD, Kaye SB, et al: Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: A prospective trial (MRC TE17). Br J Cancer 92:2107-2113, 2005
12. Pont J, Albrecht W, Postner G, et al: Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial. J Clin Oncol 14:441-448, 1996
13. Sogani PC, Perrotti M, Herr HW, et al: Clinical stage I testis cancer: Long-term outcome of patients on surveillance. J Urol 159:855-858, 1998
14. Daugaard G, Petersen PM, Rorth M: Surveillance in stage I testicular cancer. Apmis 111:76-83, 2003; discussion 83-85, 2003
15. Read G, Stenning SP, Cullen MH, et al: Medical Research Council prospective study of surveillance for stage I testicular teratoma: Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10: 1762-1768, 1992
16. Sharir S, Jewett MA, Sturgeon JF, et al: Progression detection of stage I nonseminomatous testis cancer on surveillance: Implications for the followup protocol. J Urol 161:472-475, 1999; discussion 475-476, 1999
17. Colls BM, Harvey VJ, Skelton L, et al: Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 83:76-82, 1999
18. Francis R, Bower M, Brunstrom G, et al: Surveillance for stage I testicular germ cell tumours: Results and cost benefit analysis of management options. Eur J Cancer 36:1925-1932, 2000
19. Freedman LS, Parkinson MC, Jones WG, et al: Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2:294-298, 1987
20. Gels ME, Hoekstra HJ, Sleijfer DT, et al: Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: A single-center 10-year experience. J Clin Oncol 13: 1188-1194, 1995
21. Krege S, Beyer J, Souchon R, et al: European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 53:478-496, 2008
22. Schmoll HJ, Jordan K, Huddart R, et al: Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:iv89-iv96, 2009
23. Motzer RJ, Bolger GB, Boston B, et al: Testicular cancer: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:1038-1058, 2006
24. Duran I, Sturgeon JF, Jewett MA, et al: Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). J Clin Oncol 25:240s, 2007 (abstr 5021)
25. Redelmeier DA, Shafir E: Medical decision making in situations that offer multiple alternatives. JAMA 273:302-305, 1995
26. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513-1523, 2003
27. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18: 1725-1732, 2000
28. Travis LB, Fossa SD, Schonfeld SJ, et al: Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97:1354-1365, 2005
29. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007
30. O'Connor AM, Tugwell P, Wells GA, et al: Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Making 18:295-303, 1998
31. Bhatia S, Abonour R, Porcu P, et al: High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346-3351, 2000
32. Einhorn LH, Williams SD, Chamness A, et al: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340-348, 2007
33. Kondagunta GV, Bacik J, Donadio A, et al: Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23:6549-6555, 2005
34. Kondagunta GV, Bacik J, Sheinfeld J, et al: Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 25:85-90, 2007
35. Loehrer PJ Sr, Gonin R, Nichols CR, et al: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500-2504, 1998
36. McCaffrey JA, Mazumdar M, Bajorin DF, et al: Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol 15:2559-2563, 1997
37. Albers P, Siener R, Kliesch S, et al: Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: Results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21:1505-1512, 2003
38. Behnia M, Foster R, Einhorn LH, et al: Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: The Indiana University experience. Eur J Cancer 36:472-475, 2000
39. Kondagunta GV, Sheinfeld J, Mazumdar M, et al: Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 22:464-467, 2004
40. Williams SD, Stablein DM, Einhorn LH, et al: Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433-1438, 1987
41. Heidenreich A, Sesterhenn IA, Mostofi FK, et al: Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83:1002-1011, 1998
42. Debono DJ, Heilman DK, Einhorn LH, et al: Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455-1464, 1997
43. Carver BS, Motzer RJ, Bajorin D, et al: Postchemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumors: The impact of time. J Clin Oncol 23:398s, 2005 (abstr 4581)
44. Patel MI, Beck S, Bosl GJ, et al: Histology of good risk non-seminomatous germ cell tumor patients following postchemotherapy retroperitoneal lymph node dissection after four cycles of etoposide and cisplatin. J Urol 169:176, 2003 (abstr 681)
45. Toner GC, Panicek DM, Heelan RT, et al: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 8:1683-1694, 1990
46. Fizazi K, Tjulandin S, Salvioni R, et al: Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy - Results from an international study group. J Clin Oncol 19:2647-2657, 2001
47. Spiess PE, Tannir NM, Brown GA, et al: Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology 70:1173-1178, 2007
48. Donohue JP, Foster RS: Retroperitoneal lymphadenectomy in staging and treatment: The development of nerve-sparing techniques. Urol Clin North Am 25:461-468, 1998
49. Jewett MA: Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am 17:449-456, 1990
50. Berger CC, Bokemeyer C, Schneider M, et al: Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A:2229-2238, 1995
51. Berger CC, Bokemeyer C, Schuppert F, et al: Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 73:1108-1114, 1996
52. Kollmannsberger C, Kuzcyk M, Mayer F, et al: Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 17:275-281, 1999
53. Nuver J, Smit AJ, Wolffenbuttel BHR, et al: The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23:3718-3725, 2005
54. Raghavan D, Cox K, Childs A, et al: Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 10:1386-1389, 1992
55. Vogelzang NJ, Bosl GJ, Johnson K, et al: Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95:288-292, 1981
56. Weijl NI, Rutten MF, Zwinderman AH, et al: Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature. J Clin Oncol 18:2169-2178, 2000
57. Nichols CR, Roth BJ, Williams SD, et al: No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 10:760-765, 1992
58. Russell LB, Gold MR, Siegel JE, et al: The role of cost-effectiveness analysis in health and medicine: Panel on cost-effectiveness in health and medicine. JAMA 276:1172-1177, 1996
59. Bennett KJ, Torrance GW: Measuring health state preferences and utilities: Rating scale, time trade-off, and standard gamble techniques, in Bennett KJ, Torrance GW (eds): Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA, Lippincott-Raven Publishers, 1996, pp 253-265
60. Hilton S, Herr HW, Teitcher JB, et al: CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: Assessment of size and distribution criteria. Am J Roentgenol 169:521-525, 1997
61. Leibovitch L, Foster RS, Kopecky KK, et al: Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 154:1759-1763, 1995
62. Kattan MW: Comparing treatment outcomes using utility assessment for health-related quality of life. Oncology (Williston Park) 17:1687-1693, 2003; discussion 1693-4, 1697:1701, 2003
63. Cowen ME, Miles BJ, Cahill DF, et al: The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making 18:376-380, 1998
64. Chamie K, Kurzrock EA, Romero V, et al: Increased risk of secondary malignancy in patients on surveillance for NSGCT. J Urol 179:172-173, 2008 (abstr 492)
65. Sheinfeld J, Motzer RJ: Stage I testicular cancer management and necessity for surgical expertise. J Clin Oncol 26:2934-2936, 2008